Who is eligible for clinical trial NCT04908189?

Participants must meet protocol criteria for Psoriatic Arthritis. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT04908189 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2025-06-12

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment (NCT04908189)

A Multi-center, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: Bristol-Myers Squibb

🩺 Plain-English Summary (8th-Grade Level)

The purpose of this study is to evaluate the safety and efficacy of deucravacitinib versus placebo for the treatment of participants with active PsA who are naïve to biologic disease modifying antirheumatic drugs or had previously received TNFα inhibitor treatment.The long term extension period will provide additional long-term safety and efficacy information.

Who can join: Review the eligibility criteria below.

Location: Local Institution - 0149 — Mountain Brook, Alabama

Age range: 18 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (138 Sites)

Showing the first 25 of 138 sites.

Local Institution - 0149 — Mountain Brook, Alabama
Local Institution - 0212 — Sacramento, California
Local Institution - 0188 — Whittier, California
Local Institution - 0192 — Skokie, Illinois
Local Institution - 0203 — Hopkinsville, Kentucky
Local Institution - 0195 — Baton Rouge, Louisiana
Local Institution - 0169 — Cumberland, Maryland
Local Institution - 0034 — Okemos, Michigan
Local Institution - 0133 — Eagan, Minnesota
Local Institution - 0109 — Hattiesburg, Mississippi
Local Institution - 0108 — New York, New York
Local Institution - 0186 — Rochester, New York
Local Institution - 0196 — Charlotte, North Carolina
Local Institution - 0180 — Cleveland, Ohio
Local Institution - 0189 — Oklahoma City, Oklahoma
Local Institution - 0147 — Portland, Oregon
Local Institution - 0016 — Duncansville, Pennsylvania
Local Institution - 0182 — Summerville, South Carolina
Local Institution - 0167 — Lubbock, Texas
Local Institution - 0070 — Mesquite, Texas
Local Institution - 0184 — Plano, Texas
Local Institution - 0187 — Seattle, Washington
Local Institution - 0190 — Franklin, Wisconsin
Local Institution - 0175 — Milwaukee, Wisconsin
Local Institution - 0048 — La Plata, Buenos Aires

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Psoriatic Arthritis

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs — Gilbert, Arizona
Psoriatic Arthritis D2P Screening — Philadelphia, Pennsylvania
Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis — Dothan, Alabama
Apremilast Pregnancy Exposure Registry — La Jolla, California
Psorcast Mobile Study — Seattle, Washington
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy — Anniston, Alabama

Explore by condition: All Psoriatic Arthritis clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Review the official NIH record below to find the coordinating site.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗